Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High Following Better-Than-Expected Earnings

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reached a new 52-week high during mid-day trading on Thursday following a better than expected earnings announcement. The company traded as high as $33.43 and last traded at $32.5270, with a volume of 2202319 shares trading hands. The stock had previously closed at $33.21.

The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.13% and a net margin of 4.24%.The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same quarter in the previous year, the business earned $0.71 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results materially beat expectations — Teva reported $0.96 EPS vs. $0.65 consensus and revenue of $4.71B vs. $4.36B expected; revenue rose ~11% YoY, signaling durable top-line strength. Teva Q4 earnings release and call materials
• Positive Sentiment: Profit uptick driven by branded drug sales and a milestone payment tied to a late‑stage study — this extra revenue helped lift quarterly profit and underscores pipeline monetization potential. Reuters: Teva profit, revenue rise in fourth quarter
• Positive Sentiment: Company emphasizes three consecutive years of revenue growth and an “innovative” pipeline poised to unlock value — helpful for investor sentiment around long‑term growth potential. GlobeNewswire: Teva growth and pipeline PR
• Positive Sentiment: Analyst commentary highlights TEVA as an attractive value/quality combination based on recent results and style scores — may attract value-oriented flows. Zacks: Why Teva is a strong value stock
• Neutral Sentiment: Earnings call transcript now available for detail on management commentary, volume dynamics, and pipeline timing — useful for modeling but no new headline surprises in transcript. Seeking Alpha: Q4 2025 earnings call transcript
• Neutral Sentiment: Analyst note on Q4 key metrics provides context (ROE, margins, YoY comparisons) to help refine forecasts — useful for model adjustments but not headline-moving by itself. Zacks: Q4 key metrics analysis
• Neutral Sentiment: Marketing/awareness effort: Teva partnered on a Huntington’s disease awareness campaign (Will Forte) — positive for reputation and patient engagement but unlikely to move near-term revenue materially. Yahoo Finance: Will Forte joins Teva campaign
• Negative Sentiment: FY2026 guidance came in slightly below consensus: EPS of $2.570–$2.770 (consensus ~2.71) and revenue guidance $16.4B–$16.8B vs. ~$17.0B consensus — this guidance gap is the principal near‑term risk and explains some downward pressure in reaction. GlobeNewswire: FY2026 guidance

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. The Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Scotiabank raised their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday. Truist Financial boosted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday. Jefferies Financial Group increased their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Wall Street Zen downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Sunday, January 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Buy” and a consensus price target of $35.67.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 77,400 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the sale, the director owned 367,600 shares in the company, valued at approximately $11,116,224. This trade represents a 17.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the transaction, the chief accounting officer owned 5,650 shares in the company, valued at approximately $170,630. The trade was a 68.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 622,060 shares of company stock worth $17,076,965 over the last ninety days. 0.55% of the stock is currently owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Teva Pharmaceutical Industries by 3.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company’s stock worth $382,000 after acquiring an additional 379 shares in the last quarter. Howard Bailey Securities LLC raised its holdings in shares of Teva Pharmaceutical Industries by 3.5% during the third quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock worth $292,000 after purchasing an additional 494 shares during the period. ASR Vermogensbeheer N.V. lifted its holdings in Teva Pharmaceutical Industries by 1.6% in the third quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock worth $645,000 after acquiring an additional 515 shares during the last quarter. CIBC Private Wealth Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 15.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock worth $81,000 after purchasing an additional 540 shares during the last quarter. Finally, Retirement Planning Co of New England Inc. lifted its stake in Teva Pharmaceutical Industries by 1.8% in the third quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock valued at $671,000 after buying an additional 588 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

The company has a market cap of $37.59 billion, a P/E ratio of 54.21, a PEG ratio of 1.85 and a beta of 0.66. The stock has a fifty day moving average price of $30.12 and a two-hundred day moving average price of $22.96. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.